OrbiMed’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

OrbiMed’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-2,207,245	Closed	-$2.94M	–	149
2017 Q3	$2.94M	Sell	2,207,245 -1,043,055	-32%	-$1.3M	0.03%	127
2017 Q2	$5.1M	Hold	3,250,300	–	–	0.05%	113
2017 Q1	$10.5M	Hold	3,250,300	–	–	0.12%	96
2016 Q4	$4.39M	Hold	3,250,300	–	–	0.06%	113
2016 Q3	$5.07M	Hold	3,250,300	–	–	0.06%	117
2016 Q2	$4.32M	Sell	3,250,300 -473,228	-13%	-$2.21M	0.05%	112
2016 Q1	$19.6M	Sell	3,723,528 -692,772	-16%	-$4.24M	0.21%	66
2015 Q4	$34.7M	Hold	4,416,300	–	–	0.31%	60
2015 Q3	$37.3M	Hold	4,416,300	–	–	0.38%	54
2015 Q2	$48.4M	Buy	4,416,300 +151,400	+4%	+$1.94M	0.4%	54
2015 Q1	$59.6M	Sell	4,264,900 -472,000	-10%	-$7.22M	0.51%	55
2014 Q4	$80M	Hold	4,736,900	–	–	0.76%	37
2014 Q3	$63.6M	Hold	4,736,900	–	–	0.66%	42
2014 Q2	$60.3M	Hold	4,736,900	–	–	0.71%	41
2014 Q1	$56.3M	Sell	4,736,900 -57,400	-1%	-$770K	0.69%	42
2013 Q4	$66.2M	Buy	4,794,300 +201,700	+4%	+$2.85M	0.97%	33
2013 Q3	$80M	Buy	4,592,600 +71,800	+2%	+$1.37M	1.43%	24
2013 Q2	$73.2M	Buy	+4,520,800	New	+$140M	1.55%	26

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed's INFI Position: Q4 2017 in Review

OrbiMed sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2017, closing a stake of 2,207,245 shares — an estimated $2.94M sold.

OrbiMed first reported a position in INFI in Q2 2013 and held it in 18 quarters. The position peaked at $80M in Q3 2013. 65 funds tracked by Wall St. Rank hold INFI as of Q4 2017.

OrbiMed reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
OrbiMed sold 2,207,245 Infinity Pharmaceuticals, Inc. shares in Q4 2017, an estimated $2.94M.
OrbiMed first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 18 quarters.
OrbiMed's Infinity Pharmaceuticals, Inc. position peaked at $80M in Q3 2013.
65 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2017.

Based on OrbiMed's 13F filing for Q4 2017, filed 14 Feb 2018.